NCT06202560Completed
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Institute of Dermatology, Thailand
- Participants (registry)
- 11
- Start
- November 2023
- Primary completion
- July 2024
- Study completion
- July 2024
- Last registry update
- May 2025
- Countries
- Thailand
Conditions studied: Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp
Interventions: Tofacitinib 5 MG, Xeljanz
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.